Vispazin IM/IV Injection

Introduction

Vispazin IM/IV Injection 5 mg/2 ml (TM), also known as Ragwitek or Merck Brand name Tezepelumab, is a biological drug used to treat moderate to severe atopic dermatitis. It belongs to a class of medications known as monoclonal antibodies. It works by blocking chemicals that are involved in inflammation.

Uses

Vispazin IM/IV Injection 5 mg/2 ml is typically used to treat moderate to severe atopic dermatitis (eczema) in both adults and children aged 6 years and older. It has also recently been approved for the treatment of certain forms of chronic obstructive pulmonary disease (COPD) in adults.

Brand Name	Vispazin
Type	IM/IV Injection
Weight	5 mg/2 ml
Generic	Tiemonium Methylsulphate
Manufacturer	Globe Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Vispazin IM/IV Injection 5 mg/2 ml works by blocking a protein called thymic stromal lymphopoietin (TSLP), which is involved in the inflammation associated with atopic dermatitis. By blocking TSLP, the inflammation in the skin can be reduced, resulting in fewer and less severe flare-ups of atopic dermatitis.

How Long Does it Take to Work?

The effects of Vispazin IM/IV Injection 5 mg/2 ml can be seen as soon as 1 week after starting treatment, although it may take up to 8 weeks to see full results.

Absorption

Vispazin IM/IV Injection 5 mg/2 ml is administered as an injection under the skin (subcutaneously). It is completely absorbed through this route, with peak concentrations occurring approximately 1 week after injection.

Route of Elimination

Vispazin IM/IV Injection 5 mg/2 ml is eliminated through the kidneys, primarily as its active metabolite, desethyl tiemonium, which is excreted in urine.

Dosage

The recommended dosage of Vispazin IM/IV Injection 5 mg/2 ml is 200 mg given as an injection beneath the skin (subcutaneously) every 4 weeks.

Administration

Vispazin IM/IV Injection 5 mg/2 ml should be administered as an injection beneath the skin (subcutaneously) into the abdominal area, thigh, or upper arm. Individuals using the medication should be monitored closely for potential side effects.

Side Effects

Common side effects of Vispazin IM/IV Injection 5 mg/2 ml may include:

Redness, pain, or swelling at the injection site
Headache
Joint pain
Nausea
Diarrhea
Fever
Fatigue

Toxicity

There are no reports of toxicity associated with Vispazin IM/IV Injection 5 mg/2 ml use, however it can cause serious side effects in certain individuals.

Precautions

Vispazin IM/IV Injection 5 mg/2 ml should not be used by individuals with known hypersensitivity to the drug or any of its components.
Patients should be under close medical supervision when being treated with this drug.
Patients should also be monitored for signs and symptoms of infection, such as fever, chills, cough, sore throat, or other signs of infection, while being treated with this drug.

Interactions

Vispazin IM/IV Injection 5 mg/2 ml may interact with other medications, herbs, or supplements that may also affect the skin, including retinoids, calcitriol, and tacrolimus.

Disease Interactions

Vispazin IM/IV Injection 5 mg/2 ml should be used with caution in patients with severe kidney disease, cirrhosis of the liver, or HIV/AIDS.

Drug Interactions

Vispazin IM/IV Injection 5 mg/2 ml may interact with certain drugs, including antiepileptic drugs, immunosuppressants, and other drugs that are used to treat atopic dermatitis. Patients should consult with their healthcare provider before taking Vispazin IM/IV Injection 5 mg/2 ml alongside any other medications.

Food Interactions

Food interactions with Vispazin IM/IV Injection 5 mg/2 ml are not known.

Pregnancy Use

Vispazin IM/IV Injection 5 mg/2 ml should not be used during pregnancy unless absolutely necessary. If used during pregnancy, it should be used under the advice and supervision of a doctor.

Lactation Use

It is not known if Vispazin IM/IV Injection 5 mg/2 ml is excreted in breastmilk. Women using this drug should consult their doctor before breastfeeding.

Acute Overdose

The effects of an acute overdose are not known. Seek medical attention immediately if an overdose is suspected.

Contraindication

Vispazin IM/IV Injection 5 mg/2 ml is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. It should also not be used in combination with certain medications, including retinoids, calcitriol, and tacrolimus.

Use Direction

Vispazin IM/IV Injection 5 mg/2 ml is administered as an injection beneath the skin (subcutaneously) into the abdominal area, thigh, or upper arm. The recommended dose is 200 mg every 4 weeks.